Advertisement
Advertisement
U.S. markets open in 7 hours 10 minutes
Advertisement
Advertisement
Advertisement
Advertisement

NeuBase Therapeutics, Inc. (NBSE)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Visitors trend2W10W9M
0.1860-0.0060 (-3.12%)
At close: 04:00PM EDT
0.1865 +0.00 (+0.27%)
After hours: 06:26PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Performance Outlook
Previous Close0.1920
Open0.2000
Bid0.0000 x 3000
Ask0.0000 x 1000
Day's Range0.1818 - 0.2000
52 Week Range0.1720 - 2.0800
Volume116,247
Avg. Volume375,468
Market Cap6.167M
Beta (5Y Monthly)0.89
PE Ratio (TTM)N/A
EPS (TTM)-0.8900
Earnings DateMay 10, 2023 - May 15, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for NBSE

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • NeuBase Therapeutics, Inc.
    Daily – Vickers Top Insider Picks for 03/20/2023The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Rating
    Fair Value
    Economic Moat
    20 hours agoArgus Research
View more
  • GlobeNewswire

    NeuBase Therapeutics Reports Business Update and Financial Results for the First Quarter of Fiscal Year 2023

    PITTSBURGH, Feb. 14, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, today reported its financial results for the three-month period ended December 31, 2022, and other recent developments. “We plan on leveraging our PATrOL™ platform to perform ‘nuclease free’ in vivo gene editing to restore healthy gene funct

  • American City Business Journals

    NeuBase Therapeutics selling stake in company to New York investment firm Alumni Capital

    NeuBase specializes in genetic medicine therapies that target disease-triggering DNA and RNA mutations.

  • GlobeNewswire

    NeuBase Therapeutics Reports Business Update and Financial Results for Fiscal Year 2022

    PITTSBURGH, Dec. 21, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, today reported its financial results for the fiscal year ended September 30, 2022, and other recent developments. “Fiscal year 2022 was a challenging period in our Company’s history as we faced a tightening of the broader capital markets for

Advertisement
Advertisement